Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma

David Price* (Corresponding Author), Jean Bousquet

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prescribing data for Europe show a shift from inhaled corticosteroids (ICSs) prescribed alone or in free combination with long-acting β2-agonists (LABAs) to fixed-dose single-inhaler combinations of these agents. However, existing guidelines provide little advice on selecting a specific ICS/LABA combination therapy for the treatment of asthma. European survey data indicate that the factors physicians take into account when making prescribing decisions are broadly in line with those considered to be important by experts in a Delphi process: the availability of a range of doses, the efficacy of the combination, the long-term safety and tolerability of the ICS and LABA components, the potency of the ICS and the speed of onset of the LABA. Further research is needed to help inform physician choice of ICS/LABA combinations for patients with asthma.
Original languageEnglish
Pages (from-to)S4-S8
Number of pages5
JournalRespiratory Medicine
Volume106
Issue numberSuppl 1
Early online date26 Dec 2012
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Asthma
  • Attitudinal research
  • Combination therapy
  • Inhaled corticosteroid
  • Long-acting β2-agonist
  • Prescribing trends

Fingerprint Dive into the research topics of 'Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma'. Together they form a unique fingerprint.

Cite this